Michael R. Bristow

This profile gathers the share dealings of Michael R. Bristow across 2 companies, led by Myogen Inc and Oruka Therapeutics, Inc. We count 36 filings; the first trade dates from 21 December 2005 and the latest from 4 April 2017.

Both buying and selling appear: 1 purchase worth €374k, against 18 sales worth €3.9M. On balance, insiders were net sellers of €3.5M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 5 share grants and 5 option exercises. 2017 to date brings no purchases and 2 sales.

The newest entry dates from 5 April 2017: an open-market sale of €1,625, in Oruka Therapeutics, Inc. The most recent open-market purchase was published on 28 January 2013, 5,017 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.